Human adenovirus detection in rural community water sources in central-west Brazil Graziela Picciola Bordoni1,*ORCID iD , Lucas Candido Gonçalves Barbosa2ORCID iD , Fernando Santos Lima1ORCID iD , Thais Reis Oliveira2ORCID iD , José Daniel Gonçalves Vieira1ORCID iD , Paulo Sergio Scalize3ORCID iD , Lilian Carla Carneiro1,2

https://www.academia.edu/3143-0481/2/3/10.20935/AcadImmunoDis8447 Introduction: Poor and limited access to improved water, sanitation and hygiene (WASH) services, common in rural communities in developing countries, may lead to a high burden of enteric infections and the spread of fecal organisms. In the absence of a public water distribution network, rural areas obtain their water supply from surface and/or groundwater sources, where microbial quality is often unknown. Because adenoviruses are highly persistent in water and widely distributed in the environment, they have become an important group of enteric viruses and may potentially be involved in waterborne outbreaks. https://www.academia.edu/3143-0481/2/3/10.20935/AcadImmunoDis8447?email_action=download

Challenging the Confines of Risk of Recurrence in High-Risk HR+/HER2- Early Breast Cancer Authors: Joyce A. O’Shaughnessy, MD; Priya Rastogi, MD; Seth Wander, MD, PhD

https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?page=1&src=mkmcmr_driv_stan_mscpedu_261023-OUS-HONC-challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3-cta&uac=148436CN

Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptoms (+++ +++ +++ +++)

Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptoms https://www.news-medical.net/news/20261012/Year-long-trial-finds-NAD-boosting-supplement-fails-to-improve-early-Parkinsons-symptoms.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptomsIn a phase 3 randomized clinical trial involving 410 people with early Parkinson disease, 52 weeks of nicotinamide riboside supplementation increased blood NAD levels but failed to improve clinical outcomes compared with placebo. Participants receiving the supplement had modestly worse overall disease scores, although the difference was below the threshold generally considered clinically meaningful. People who walk more each day tend to score better on several brain tests https://www.news-medical.net/news/20261014/People-who-walk-more-each-day-tend-to-score-better-on-several-brain-tests.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 People who walk more each day tend to score better on several brain testsResearchers analyzed 14 years of physical activity and blood pressure records from 3,093 US adults and found that higher daily step counts were associated with better performance on tests of attention, cognitive control, and reward-related decision-making. Higher systolic blood pressure was associated with poorer delay-discounting performance, but accounted for only 4. Epilepsy linked to higher risk of young-onset dementia https://www.news-medical.net/news/20261014/Epilepsy-linked-to-higher-risk-of-young-onset-dementia.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Epilepsy linked to higher risk of young-onset dementiaPeople with epilepsy may be more likely to develop young-onset dementia than people without epilepsy, according to a study published October 14, 2026, in Neurology®, the medical journal of the American Academy of Neurology. Hybrid AI architecture improves seizure prediction using EEG signals https://www.news-medical.net/news/20261013/Hybrid-AI-architecture-improves-seizure-prediction-using-EEG-signals.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Hybrid AI architecture improves seizure prediction using EEG signalsEpilepsy affects about 50 million people worldwide and can seriously affect patients' quality of life. Electroencephalography (EEG), which records the brain's electrical activity in real time, plays an important role in epilepsy diagnosis and monitoring. Recurrent brain tumors undergo unique genetic changes after treatment https://www.news-medical.net/news/20261014/Recurrent-brain-tumors-undergo-unique-genetic-changes-after-treatment.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Recurrent brain tumors undergo unique genetic changes after treatmentWhen patients are diagnosed with certain brain tumors, one of the biggest unanswered questions is what happens when the cancer returns. 16-year study links worsening vision to higher dementia risk https://www.news-medical.net/news/20261011/16-year-study-links-worsening-vision-to-higher-dementia-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 16-year study links worsening vision to higher dementia riskResearchers followed 15,576 older adults in Hong Kong for up to 16 years and linked moderate to severe visual impairment to higher dementia risk, with rapid visual decline strengthening the association at poorer levels of vision. They estimated that severe impairment corresponded to 2.1 fewer dementia-free years over the study period, but could not establish that correcting vision prevents dementia. Study finds both the liver and brain drive distinct symptoms of rare genetic epilepsy https://www.news-medical.net/news/20261009/Study-finds-both-the-liver-and-brain-drive-distinct-symptoms-of-rare-genetic-epilepsy.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study finds both the liver and brain drive distinct symptoms of rare genetic epilepsyA recent study from Johns Hopkins Medicine reveals that both the liver and brain contribute pathways to differing symptoms of the same rare inherited disorder. Routine blood test may offer clues to future dementia risk https://www.news-medical.net/news/20261009/Routine-blood-test-may-offer-clues-to-future-dementia-risk.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Routine blood test may offer clues to future dementia riskA common blood test already carried out during routine health checks may contain clues about a person's long-term risk of dementia, according to research being presented at the ECNP Congress in Munich and recently published in the Journal of Alzheimer's Disease. Study uncovers a protective role for microglia in Parkinson's disease https://www.news-medical.net/news/20261007/Study-uncovers-a-protective-role-for-microglia-in-Parkinsons-disease.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study uncovers a protective role for microglia in Parkinson's diseaseResearchers at the University of Oxford have uncovered a previously unrecognized protective role for microglia, the brain's resident immune cells, in Parkinson's disease. Study reveals how different plant saponins alleviate ischemic stroke https://www.news-medical.net/news/20261012/Study-reveals-how-different-plant-saponins-alleviate-ischemic-stroke.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study reveals how different plant saponins alleviate ischemic strokeIschemic stroke accounts for approximately 85% of all strokes and remains a major cause of death and long-term disability. Study links abnormal immature astroglia to lower fluid intelligence in older epilepsy patients https://www.news-medical.net/news/20261020/Study-links-abnormal-immature-astroglia-to-lower-fluid-intelligence-in-older-epilepsy-patients.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Study links abnormal immature astroglia to lower fluid intelligence in older epilepsy patientsA new USC-led study links abnormal immature astroglia, star-shaped cells that support brain function, to lower fluid intelligence, or the ability to solve new problems, in older adults with epilepsy. Adults with ADHD face higher risk of developing dementia later in life https://www.news-medical.net/news/20261007/Adults-with-ADHD-face-higher-risk-of-developing-dementia-later-in-life.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Adults with ADHD face higher risk of developing dementia later in lifeA new study led by University of Pittsburgh School of Medicine researchers finds that adults with attention-deficit/hyperactivity disorder (ADHD) face a significantly higher risk of developing dementia or mild cognitive impairment later in life.

Plasma eMTBR-Tau: Advancing Blood-Based Tau Tangle Research

https://spear.bio/resource/blog/plasma-emtbr-tau-tangle-biomarker/?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=neurology_and_neuroscience_newsletter_21_october_2026 Explore how plasma eMTBR-Tau complements pTau 217 in Alzheimer’s research. Discover findings generated using Spear Bio’s SPEAR TrueDetect™ eMTBR-Tau assay, linking blood measurements to autopsy-confirmed tau pathology, tau PET, and cognitive decline—with strong classification performance across blood samples collected up to a decade before death.

Women and men face different heart attack risks with diabetes

https://www.news-medical.net/news/20261023/Women-and-men-face-different-heart-attack-risks-with-diabetes.aspx A study spanning four decades reveals how cholesterol abnormalities and high blood pressure help explain differences in diabetes-related heart attack risk between women and men, with warning signs emerging years before diabetes is diagnosed. A study published in European Heart Journal Open reported that the relative increase in myocardial infarction, or heart attack, risk associated with diabetes was similar in women and men after adjustment for conventional cardiovascular risk factors. The initially observed sex difference narrowed after adjustment for these factors, whose combined contribution was greater in women than in men.

Maqui Berry: Health Benefits, Nutrition, and Uses (+++)

Maqui Berry: Health Benefits, Nutrition, and Uses https://www.news-medical.net/health/Maqui-Berry-Health-Benefits-Nutrition-and-Uses.aspx From its purple pigments to its interactions with gut bacteria, maqui berry raises scientific questions about how plant compounds influence cellular defenses and human health. The maqui berry, which grows in the temperate rainforests of southern Chile and Argentina, has a higher anthocyanin content than many other berries.1,9 Historically, Mapuche communities in southern Chile used maqui preparations, particularly those made from leaves, for wound care and fever, with modern researchers increasingly exploring this fruit as a source of antioxidant compounds.1 Jaboticaba Fruit: What Are Its Potential Health Benefits? https://www.news-medical.net/health/Jaboticaba-Fruit-What-Are-Its-Potential-Health-Benefits.aspx Beneath jaboticaba’s dark-purple skin lies a mixture of fiber and plant compounds that raises questions about digestion, blood sugar, and the gap between laboratory findings and human health. Jaboticaba is a dark-purple fruit that grows directly on the trunks and branches of trees native to the Brazilian Atlantic Forest. Emerging evidence suggests that anthocyanins, ellagitannins, and other bioactive compounds in jaboticaba may influence inflammatory pathways and the gut microbiota, primarily in laboratory and animal studies.1,3,7 How GLP-1 Drugs Affect the Brain Beyond Weight Loss https://www.news-medical.net/health/How-GLP-1-Drugs-Affect-the-Brain-Beyond-Weight-Loss.aspx What happens when a metabolic treatment reaches the brain's appetite, reward, and memory systems? Researchers are examining where these effects begin and what they could mean for neurological care. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) were initially designed to improve glycemic control in people with type 2 diabetes. Research now suggests that these drugs may also influence mood, reward processing, cognition, and processes implicated in neurodegenerative diseases.1

Scientists studied one million immune cells and found clues to future disease risk

https://www.news-medical.net/news/20261022/Scientists-studied-one-million-immune-cells-and-found-clues-to-future-disease-risk.aspx A sweeping analysis of the body's most abundant white blood cells examines how their molecular differences relate to serious illness, metabolic health, and the risk of future disease. A recent study published in the journal Nature Immunology presents a single-cell atlas of human neutrophils (SCAHN), offering new insights into how these immune cells behave in health and disease. The researchers linked neutrophil gene activity patterns to cancer outcomes, metabolic health, and the risk of death over the long term. These patterns also helped identify mortality risk among individuals with acute illness at hospital presentation. The findings suggest that neutrophil profiling may eventually contribute to clinical risk assessment, pending prospective validation.

Sharing the Decision of Treatment Planning in High-Risk HR+/HER2- Early Breast Cancer Authors: Shaheenah Dawood, MBBCh, MPH, FACP

https://www.medscape.org/viewarticle/sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67?page=1&src=mkmcmr_driv_stan_mscpedu_261022-OUS-HONC-sharing-decision-treatment-planning-high-risk-hr-her2-early-2026a1000f67-cta&uac=148436CN

FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph?utm_medium=email&utm_source=govdelivery On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.

A microglial transition could mean the difference between a healthy brain and Alzheimer’s disease Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity. Written byAllison Whitten, PhD

A microglial transition could mean the difference between a healthy brain and Alzheimer’s disease Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/a-microglial-transition-could-mean-the-difference-between-a-healthy-brain-and-alzheimer-s-disease-17273?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_qwl0FiYdzQ0FjoF5pHFPPnwt1-88MP98J41WMyAvrK2bw2GVkJC7D-Ujak870yfzN5TIVKxxvnHuN3QfXiMv16ggafg&_hsmi=445381586&utm_content=445381586&utm_source=hs_email Whether or not someone develops Alzheimer’s disease could be the result of a key transition in microglial activity, according to new research published recently in Nature Medicine. Researchers led by Mark Fiers and Bart De Strooper at the VIB-KU Leuven Center for Neuroscience and University College London, in collaboration with Muna Therapeutics, found that microglia switch from an early inflammatory response in the presence of amyloid plaques to an antigen-presenting state that coincides with the development of tau tangles. Fiers told DDN that the work “started from an observation that has mystified the field for years: Many people have a brain full of amyloid but never get dementia.” The research team wanted to use spatial transcriptomics techniques to specifically study what goes on in the brain around amyloid plaques. Their work revealed that the postmortem brains of octogenarians and centenarians who did not show cognitive symptoms of Alzheimer’s disease — despite having the classic pathology in their brains — diverged in their patterns of microglial resilience.

Could overlooked bacterial DNA help explain aggressive prostate cancer? Bacterial genomes recovered from discarded DNA sequencing data could help researchers investigate whether microbes contribute to aggressive prostate cancer. Written byBree Foster, PhD

Could overlooked bacterial DNA help explain aggressive prostate cancer? Bacterial genomes recovered from discarded DNA sequencing data could help researchers investigate whether microbes contribute to aggressive prostate cancer. Written byBree Foster, PhD https://www.drugdiscoverynews.com/could-overlooked-bacterial-dna-help-explain-aggressive-prostate-cancer-17595 When researchers sequence DNA from a tumor or blood sample, they typically focus on the patient's genetic material. Sequences that do not map to the human genome are often filtered out, but researchers are increasingly recognizing that these unmapped sequences actually contain a wealth of valuable information. A growing body of evidence has linked certain bacteria to cancer, with some microbes implicated in cancer development and others associated with disease progression. Now, researchers at the University of East Anglia (UEA) have investigated whether this overlooked DNA could help uncover previously uncharacterized bacterial species in patients with prostate cancer.

Moving beyond single targets in neurological repair Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability. Written byBree Foster, PhD

Moving beyond single targets in neurological repair Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability. Written byBree Foster, PhD https://www.drugdiscoverynews.com/moving-beyond-single-targets-in-neurological-repair-17486?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-84vh7nMnqBm_u_j5cWuYWwR2LB3ayuwP5bDn4TmL9jTrTE07waLIhOe5plsoVw0cSuLMmcot2yPPWTIo4jHb5J0A70sA&_hsmi=445381586&utm_content=445381586&utm_source=hs_email Stroke is a leading cause of long-term disability worldwide, leaving many survivors with persistent impairments despite advances in acute treatment and rehabilitation. A key determinant of post-stroke recovery is the brain’s ability to reorganize its structure and function following injury, known as neuroplasticity. This process involves a complex network of interacting mechanisms, including changes in synaptic connections, neural circuitry, blood vessel formation, and inflammation. However, harnessing these separate mechanisms is extremely difficult.

A tuberculosis vaccine could hold clues to tackling dementia BCG vaccination reduced tau pathology and neuroinflammation in mice, prompting researchers to investigate whether trained immunity could inform future treatments for Alzheimer’s disease. Written byBree Foster, PhD

A tuberculosis vaccine could hold clues to tackling dementia BCG vaccination reduced tau pathology and neuroinflammation in mice, prompting researchers to investigate whether trained immunity could inform future treatments for Alzheimer’s disease. Written byBree Foster, PhD https://www.drugdiscoverynews.com/a-tuberculosis-vaccine-could-hold-clues-to-tackling-dementia-17597 First administered to a human infant in 1921, the Bacillus Calmette–Guérin (BCG) vaccine was developed to protect against tuberculosis. More than a century later, BCG remains the only licensed vaccine against tuberculosis and is now used for a range of conditions, including leprosy and bladder cancer. Now, researchers are investigating whether the vaccine could also treat neurodegenerative disease. Several retrospective studies have linked BCG treatment for bladder cancer with a lower incidence of dementia, although these findings cannot establish that the vaccine itself is responsible. In a new study, researchers at Johns Hopkins University School of Medicine explored this connection in mice with tauopathy, a group of brain disorders characterized by the abnormal accumulation of tau protein.

FDA approves GSK's functional cure for hepatitis B Clinical trial updates, regulatory approvals, and more led the news this week. Brought to you byDDN editorial team

FDA approves GSK's functional cure for hepatitis B Clinical trial updates, regulatory approvals, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/fda-approves-gsk-s-functional-cure-for-hepatitis-b-17600 Tuesday brought good news for many patients with chronic hepatitis B. GSK’s antisense oligonucleotide Hibsago (bepirovirsen) injection received the green light from the FDA, effectively offering a chance for some people with chronic hepatitis B to stop taking their antivirals entirely. The approval was based on two Phase 3 B-WELL trials, which demonstrated that 24 percent of patients who received the Hibsago treatment qualified to stop taking their medications — compared to zero percent taking the placebo. After 24 weeks without antivirals, Hibsago led to a functional cure in 19 percent of patients who no longer had detectable viral proteins in their blood. “Hibsago provides a new treatment approach that gives some patients the possibility of maintaining control of the virus after all chronic HBV treatment has ended. This approval represents an important advance for people living with this serious disease,” said Wendy Carter, Acting Director of the Office of Infectious Diseases in the Center for Drug Evaluation and Research, in the press release. The approval marks the first to reach the finish line in a competitive landscape, with therapeutic options for hepatitis B from companies like Brii Biosciences now lagging behind. – Allison Whitten

Navigating Next Steps in CLL: A Collaborative Dialogue Authors: Chaitra Ujjani, MD

https://www.medscape.org/viewarticle/navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261022-OUS-HONC-navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d-cta

Most Read Cancer Science & Oncogenesis (+...)

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_261023

Comment p1674 Mitapivat in the RISE UP trial: a new therapy for sickle cell disease Jennifer Knight-Madden,Zachary Ramsay (+...)

Comment p1674 Mitapivat in the RISE UP trial: a new therapy for sickle cell disease Jennifer Knight-Madden,Zachary Ramsay https://www.thelancet.com/journals/lancet/issue/vol408no10565/PIIS0140-6736(26)X2040-2

FDA Approves New Formulation of Sjörgen’s Disease Treatment by Madaline Spencer| Published on: Oct 23, 2026

https://checkrare.com/fda-approves-new-formulation-of-sjorgens-disease-treatment/ The US Food and Drug Administration (FDA) has approved Evoxac (cevimeline HCI) oral solution to address dry mouth in patients with Sjögren’s disease (SjD). SjD is an autoimmune disorder that largely impacts secretory glands. It is also associated with rheumatic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Hallmark symptoms include dry mouth and dry eyes, but the condition may cause skin, nose, and vaginal dryness. SjD may also affect other organs of the body including the kidneys, blood vessels, lungs, liver, pancreas, and brain.

Know Your Nutrition

Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims

Modus Therapeutics: SEVUSMART study of sevuparin in children with severe malaria published in Nature Communications

https://www.news-medical.net/news/20261022/Modus-Therapeutics-SEVUSMART-study-of-sevuparin-in-children-with-severe-malaria-published-in-Nature-Communications.aspx Modus Therapeutics Holding AB (publ) announces that the manuscript based on the Phase Ib study SEVUSMART in severe malaria, lead-authored by Professor Kathryn Maitland of Imperial College London with co-authors from the SMAART consortium including members such as University College London and the University of Oxford, has been published today in the peer-reviewed journal Nature Communications, following independent peer review. The manuscript was submitted in June 2026 and made available ahead of peer review as a preprint via Research Square.

Artificial intelligence in stroke rehabilitation: A structured clinical review

https://www.news-medical.net/news/20261022/Artificial-intelligence-in-stroke-rehabilitation-A-structured-clinical-review.aspx Stroke is a major cause of long-term disability, and recovery varies substantially across motor, cognitive, communication, and activities-of-daily-living domains, making continuous assessment and individualized rehabilitation essential. However, current rehabilitation decisions still rely heavily on periodic clinical scales, clinician experience, and local resources, which may not fully capture differences in lesion characteristics, baseline function, comorbidities, and recovery trajectories. Access is also limited by geographic barriers, uneven service capacity, and intermittent follow-up.

Can GLP-1 Drugs Help Treat Osteoarthritis and Relieve Joint Pain?

https://www.news-medical.net/health/Can-GLP-1-Drugs-Help-Treat-Osteoarthritis-and-Relieve-Joint-Pain.aspx Researchers are investigating how appetite- and blood-glucose-regulating drugs interact with cartilage, inflammation, and osteoarthritis biology. Osteoarthritis (OA) is the most common joint disorder and a leading cause of pain and disability worldwide. This condition is characterized by progressive degeneration of articular cartilage, accompanied by changes in subchondral bone, synovium, and other joint tissues.

How GLP-1 Drugs Affect Cancer Risk: Evidence, Mechanisms, and Safety

https://www.news-medical.net/health/How-GLP-1-Drugs-Affect-Cancer-Risk-Evidence-Mechanisms-and-Safety.aspx Can metabolic treatments change cancer risk? Studies of GLP-1 receptor agonists examine how weight loss, insulin regulation, and tumor biology may intersect. Since their approval, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have improved management of metabolic conditions such as obesity and type 2 diabetes (T2D). Given the well-established association between weight loss and reduced cancer risk, researchers are investigating whether these drugs could also protect against cancer.

What Is Inflammaging? Causes, Health Effects, and Ways to Reduce Inflammation

https://www.news-medical.net/health/What-Is-Inflammaging-Causes-Health-Effects-and-Ways-to-Reduce-Inflammation.aspx As the body ages, subtle changes in immune function can fuel persistent inflammation. Scientists are uncovering the cellular processes behind this phenomenon and investigating whether diet, exercise, and emerging therapies could change its course. Acute inflammation is a protective immune response to injury or infection that normally resolves after the trigger is cleared and tissue repair proceeds. Chronic inflammation can develop when inflammatory triggers persist, or the mechanisms that regulate and resolve inflammation become impaired.1

Are shared fryers really off-limits for people with celiac disease?

https://www.news-medical.net/news/20261022/Are-shared-fryers-really-off-limits-for-people-with-celiac-disease.aspx French fries and tortilla chips cooked alongside gluten-containing foods may not always pose the risk previously assumed, as new research finds that most samples contained low gluten levels, with fryer oil changes emerging as a potentially important factor. People with celiac disease are commonly advised to avoid foods prepared in fryers also used for gluten-containing foods. However, a recent study published in Nutrients found that most French fries and tortilla chips prepared in shared fryers contained gluten levels below the US regulatory threshold for gluten-free labeling, suggesting that contamination risk may be lower than commonly assumed in some food-service settings.

Safeguarding paediatric metabolic health The Lancet Diabetes & Endocrinology (+...)

Safeguarding paediatric metabolic health The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/issue/vol14no11/PIIS2213-8587(26)X2009-5

Academy of Medical Sciences | The Lancet International Health Lecture 2026: The future of global health in a rapidly changing world Nov 4, 2026 2:45pm GMT In-person and online Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE, UK

https://acmedsci.my.salesforce-sites.com/es/event/home/ihl2026online?utm_medium=email&_hsenc=p2ANqtz-_EtyEviBOxZ-As0clBZhTtPZd2kx2XSubOARhgTS7uqYEB7eKa_oL2n4Hmr10c63IWV2DN9fRVzwWxh8NuLwD28PRl5Q&_hsmi=443950502&utm_content=443870169&utm_source=hs_email#registerNow We are delighted to invite you to the Academy of Medical Sciences | The Lancet International Health Lecture 2026, featuring a keynote lecture from Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance, on the future of global health in a rapidly changing world. You are welcome to join us in person at the Royal Society of Medicine, London, or online if more convenient. This is a public event open to all who are interested.

Converging arboviral outbreaks demand disease-agnostic public health responses eBioMedicine (+...)

Converging arboviral outbreaks demand disease-agnostic public health responses eBioMedicine https://www.thelancet.com/journals/ebiom/issue/vol132nonull/PIIS2352-3964(26)X2008-4

Reshaping Gastroesophageal Adenocarcinoma Care: Integrating New Anti-HER2 Therapies CME/CNE/CPE/IPCE Monday, November 9, 2026 | 3:30 pm - 4:15 pm ET Virtual

https://na.eventscloud.com/website/99132/ Transform your gastroesophageal adenocarcinoma (GEA) practice by joining expert oncologists Elena Elimova, Samuel J. Klempner, and Kohei Shitara for an interactive, 45-minute online discussion. Unpack the latest clinical trial data for novel anti-human epidermal growth factor receptor 2 (HER2) regimens, learn how to integrate new frontline regimens into care for patients with HER2-positive GEA, and gain insight into postprogression strategies. Faculty will also discuss proactive team-based approaches to toxicity management. Register now to elevate your clinical decision-making.

Screening Smarter: Moving Beyond Uniform Breast Cancer Detection Strategies Authors: Therese Bartholomew Bevers, MD; Laura Esserman, MD, MBA

https://www.medscape.org/viewarticle/screening-smarter-moving-beyond-uniform-breast-cancer-2026a10010rw?page=1&src=wnl_tpal_261021_mscpedu&uac=148436CN&impID=8818913 Funded by the U.S. Department of Health and Human Services, Office on Women’s Health

Allergies and Autoimmune Diseases: New Clues to a Shared Immune Dysfunction Brittany Vargas

https://www.medscape.com/viewarticle/allergies-and-autoimmune-diseases-new-clues-shared-immune-2026a10013ge?ecd=wnl_edit_tpal_etid8820268&uac=148436CN&impID=8820268 Allergic and autoimmune disorders have long been considered opposing forms of immune dysfunction, traditionally evaluated and treated separately. But growing evidence is challenging that distinction, revealing shared underlying mechanisms that could change how clinicians evaluate, manage, and potentially prevent both types of disease.

ACOG Releases Updated Guidance on Menopause Symptom Management Tara Haelle

https://www.medscape.com/viewarticle/acog-releases-updated-guidance-menopause-symptom-management-2026a10013fw?ecd=wnl_edit_tpal_etid8820268&uac=148436CN&impID=8820268 Updated guidance on managing menopause-related vasomotor, sleep, and mood symptoms has been released by the American College of Obstetricians and Gynecologists, providing clinicians with a summary of the most current evidence on hormonal, nonhormonal, and nonpharmacologic options. The updated guidance covers the most recent data associated with risks of systemic hormonal therapy, including types that have only become available since the last guideline in 2014, according to Catherine Cansino, MD, MPH, chair of the ACOG Committee on Clinical Practice Guidelines in Gynecology.

From Resection to Dose Individualized Antigen-Directed Therapeutics in Immuno-Oncology CME Phoenix Convention Center Saturday, November 7, 2026 | 12:30 pm - 1:30 pm MT

https://na.eventscloud.com/website/100106/ Messenger RNA (mRNA)-based therapeutics have moved from concept into clinical evaluation across immuno-oncology. This symposium discusses how mRNA-encoded, antigen-directed approaches generate anti-tumor immunity, and how they sit alongside checkpoint inhibition, cell therapy and other novel modalities. Faculty will cover the mechanistic basis of mRNA therapies — antigen selection and prediction, delivery, and the resulting T-cell priming and expansion — and how this differs from other immunotherapeutic approaches. The program will review current clinical evidence across tumor types and disease settings, including earlier-stage and minimal residual disease contexts, matching the strength of each conclusion to the design that produced it. Sessions will also address biomarker and patient-selection considerations, including tumor mutational burden, neoantigen burden and circulating tumor DNA (ctDNA)-based measures, and the multidisciplinary requirements of delivering individualized therapies in practice. The From Resection to Dose: Individualized Antigen-Directed Therapeutics in Immuno-Oncology, content and views expressed therein are those of Medscape Education and not of SITC.

Oncology Cases & Quizzes Skill Checkup: Man With Unresponsive BRAF-Positive Melanoma (+...)

Oncology Cases & Quizzes Skill Checkup: Man With Unresponsive BRAF-Positive Melanoma A 54-year-old man with BRAF-positive metastatic melanoma has not responded to anti-PD-1 or targeted therapy. His constitution is deteriorating. How would you manage this patient? Medscape Reference, October 21, 2026 https://www.medscape.com/index/list_12039_0

Medscape Medical News X-Linked Ichthyosis Not Linked to Heart Problems in Kids (+...)

Medscape Medical News X-Linked Ichthyosis Not Linked to Heart Problems in Kids X-linked ichthyosis is not associated with serious heart rhythm problems or new structural heart problems in children, a small study finds. Medscape Medical News, October 22, 2026 https://www.medscape.com/index/list_11861_0

Oncology News Chemo-Free Combo Shows Promise for Older Patients With DLBCL (+...)

Oncology News Chemo-Free Combo Shows Promise for Older Patients With DLBCL A new study evaluates a chemotherapy-free combination of two antibody-based treatments as a first-line approach in older, unfit or frail patients with newly diagnosed large B-cell lymphoma. Medscape Medical News, October 22, 2026 https://www.medscape.com/index/list_13474_0

Could Retatrutide Break a GLP-1 Weight-Loss Plateau? Julie Peck

https://www.medscape.com/viewarticle/could-retatrutide-break-glp-1-weight-loss-plateau-2026a10013ek?ecd=WNL_trdalrt_pos1_ous_261022_etid8820927&uac=148436CN&impID=8820927 In May, Eli Lilly released its phase 3 clinical trial results for retatrutide, which have generated considerable excitement across the endocrinology and obesity medicine communities. The pivotal TRIUMPH-1 trial demonstrated an average weight loss of 28.3% of body weight at 80 weeks with the highest studied dose, reaching levels historically associated with bariatric surgery. Subsequent readouts from the TRIUMPH program, including detailed findings published in September, have continued to showcase powerful efficacy across diverse populations.

Hope for efficacious vaccines for Bundibugyo virus The Lancet Infectious Diseases (+...)

Hope for efficacious vaccines for Bundibugyo virus The Lancet Infectious Diseases https://www.thelancet.com/journals/laninf/issue/vol26no11/PIIS1473-3099(26)X2010-2

FDA Approves Enspryng, the First At-Home Treatment Option for Thyroid Eye Disease by Madaline Spencer| Published on: Oct 22, 2026

https://checkrare.com/fda-approves-enspryng-the-first-at-home-treatment-option-for-thyroid-eye-disease/

Microdosing LSD shows some cognitive benefits — but only for women Different effects of low-dose psychedelics on sustained attention in women and men deserve further investigation. By Gemma Conroy

https://www.nature.com/articles/d41586-026-03265-y?utm_source=Live+Audience&utm_campaign=b691f2a608-nature-briefing-daily-20261020&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Chart showing the results of assessing the effects of the psychedelic drug LSD on cognitive function in a group of healthy participants: 24 women and 24 men. The drug significantly decreased the number of attention lapses that women experienced during a 10-minute task — an effect that wasn’t seen in men. Tiny doses of the psychedelic drug LSD seem to boost some elements of cognition — but only in women. In a small trial, women who took 15 micrograms of the drug focused for longer periods and responded faster to a stimulus than did those who were given a placebo. This trial alone can’t confirm that LSD was behind these benefits, but the signal “warrants further investigation”, says psychopharmacologist Mikkel Højlund.

Will this sleep-disorder drug be the next big blockbuster? Orexin agonists have been approved for the treatment of a type of narcolepsy, yet they could also treat conditions across the health spectrum. By Amanda Heidt

https://www.nature.com/articles/d41586-026-03310-w?utm_source=Live+Audience&utm_campaign=b691f2a608-nature-briefing-daily-20261020&utm_medium=email&utm_term=0_-33f35e09ea-50432164 In August, a type of drug called an orexin agonist was approved by US regulators to treat narcolepsy — the first of what researchers hope will be many uses for this class of drug. Several pharma companies are already exploring the effectiveness of orexin agonists to treat conditions beyond sleep disorders, such as attention deficit hyperactivity disorder (ADHD). “Diabetes was the tip of the iceberg for GLP-1s, and I’m convinced the same story will play out for orexin,” says Andrew Plump, president of research and development at pharmaceutical company Takeda.

Longevity Boom: How to Respond When ‘Normal’ Isn’t Enough (+++ +++)

Longevity Boom: How to Respond When ‘Normal’ Isn’t Enough Medscape Medical News Outside My Specialty https://www.medscape.com/viewarticle/longevity-boom-how-respond-when-normal-isnt-enough-2026a10012h5?ecd=wnl_oms_ous_all_en_etid8811805_261019_1&uac=148436CN&impID=8811805 How Are Stress, Depression, and Cardiovascular Risk Linked? Medscape News Europe Outside My Specialty https://www.medscape.com/viewarticle/how-are-stress-depression-and-cardiovascular-risk-linked-2026a10012b3?ecd=wnl_oms_ous_all_en_etid8811805_261019_2&uac=148436CN&impID=8811805 Beyond CGRP: The Search for Migraine’s Next Big Target Medscape Medical News Outside My Specialty https://www.medscape.com/viewarticle/beyond-cgrp-search-migraines-next-big-target-2026a100125z?ecd=wnl_oms_ous_all_en_etid8811805_261019_3&uac=148436CN&impID=8811805 Low-Calorie Diet/Exercise Intervention May Drive Diabetes Into Remission Medscape Medical News Outside My Specialty https://www.medscape.com/viewarticle/low-calorie-diet-exercise-intervention-may-drive-diabetes-2026a10012cw?ecd=wnl_oms_ous_all_en_etid8811805_261019_4&uac=148436CN&impID=8811805 Medscape Poll: New Targets in Migraine: Where Do They Fit in Your Practice? Medscape Reader Polls Outside My Specialty https://www.medscape.com/viewarticle/medscape-poll-new-targets-migraine-where-do-they-fit-your-2026a100120m?ecd=wnl_oms_ous_all_en_etid8811805_261019_5&uac=148436CN&impID=8811805 Functional Dyspepsia or GLP-1 Adverse Effect? How to Tell Medscape Europe https://www.medscape.com/viewarticle/functional-dyspepsia-or-glp-1-adverse-effect-how-tell-2026a10012c7?ecd=wnl_oms_ous_all_en_etid8811805_261019_6&uac=148436CN&impID=8811805

Roivant says closely watched immune drug succeeded in new eye disease Non-infectious uveitis was the next test for Lisraya pill

https://www.statnews.com/2026/10/21/roivant-immune-drug-lisraya-noninfectious-uveitis-trial-results/ By Jason MastOct. 21, 2026 General Assignment Reporter

How knocking on doors can help beat measles — again America pushed back on diseases by building trust door by door. Let’s go back to that model

https://www.statnews.com/2026/10/21/measles-public-health-door-to-door-initiatives/ By Raj PanjabiOct. 21, 2026 Panjabi is a Harvard Medical School and Mass General Brigham physician, adviser to the Governors Public Health Alliance, and former White House senior director for global health security and biodefense at the National Security Council.

The impact of PCSK9 inhibitors and what physicians really need to know

https://www.statnews.com/sponsor/2026/10/02/the-impact-of-pcsk9-inhibitors-and-what-physicians-really-need-to-know/

Replication is necessary even if scientists do everything right The NIH is pulling back on plans to prioritize replication. That’s a bad idea

https://www.statnews.com/2026/10/21/nih-replication-process-type-1-error-bhattacharya/ By Mark Louie F. RamosOct. 21, 2026 Ramos is an assistant research professor in the Department of Health Policy and Administration at Pennsylvania State University.

Patients Taking GLP-1s Face a Double Dose of Stigma

https://www.medscape.com/viewarticle/patients-taking-glp-1s-face-double-dose-stigma-2026a10012zi?ecd=WNL_trdalrt_pos1_ous_261020_etid8813672&uac=148436CN&impID=8813672 GLP-1 medications have surged in popularity, transforming treatment for obesity and diabetes and showing promise for a growing range of other conditions. According to Gallup, an estimated 11% of US adults are currently taking GLP-1s for weight loss, nearly four times the rate since 2024. But despite their clinical benefits, people taking GLP-1s can face a double stigma: criticism related to their body size and judgment for using medication to lose weight. These attitudes may influence whether patients disclose their GLP-1 use, how they discuss treatment with others, and even their healthcare decisions.

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women (+++)

https://www.fda.gov/news-events/press-announcements/fda-approves-once-weekly-generic-hormone-therapy-patch-women?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration yesterday approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products. “Menopause is a universal experience for women, and it can greatly affect a person’s quality of life. This approval makes effective treatment more accessible,” said Acting FDA Commissioner Kyle Diamantas, J.D. “Approvals like this reflect FDA’s ongoing commitment to expanding American patient access to safe, affordable, high-quality medications.” https://www.fda.gov/about-fda/what-we-do/fdas-public-health-pillars?utm_medium=email&utm_source=govdelivery The generic estradiol and levonorgestrel transdermal system is therapeutically equivalent to Climara Pro, which is indicated for use in women with an intact uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause Prevention of postmenopausal osteoporosis Climara Pro and the generic estradiol and levonorgestrel transdermal system contain both estrogen and progestogen in a single patch; this differs from estrogen-only patches commonly used in menopause treatment. Climara Pro and the generic estradiol and levonorgestrel transdermal system are specifically approved for women with an intact uterus, as the progestogen component is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone. “Once-weekly dosing can make a real difference in how patients manage their care,” said Michael Davis, M.D., Ph.D., Director of FDA's Center for Drug Evaluation and Research. “A patch offers a convenient alternative to daily oral medications, which may help patients stay on track with their treatment.” https://www.fda.gov/drugs/guidance-compliance-regulatory-information/fda-drug-competition-action-plan?utm_medium=email&utm_source=govdelivery Climara Pro and the generic estradiol and levonorgestrel transdermal system are contraindicated in patients with undiagnosed abnormal genital bleeding; breast cancer or a history of breast cancer; estrogen-dependent neoplasia; active deep vein thrombosis (DVT), pulmonary embolism (PE) or a history of these conditions; active arterial thromboembolic disease or a history of these conditions; known anaphylactic reaction or angioedema or hypersensitivity to estradiol and levonorgestrel; hepatic impairment or disease; and protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders. The most common adverse reactions (greater than or equal to 5%) are: application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome. In the U.S., nine out of 10 prescriptions filled are for generic drugs. Increasing the availability of generic drugs helps to create competition in the marketplace, which then helps to make treatment more affordable and increases access to healthcare for more patients. Learn more about the FDA Drug Competition Action Plan. Climara Pro is a registered trademark of Bayer. The FDA approved Zydus Pharmaceuticals (USA) Inc.’s Estradiol and Levonorgestrel Transdermal System. Please contact the manufacturer for information about the medicine’s availability.

FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment New treatment may allow some patients to maintain viral control after stopping all hepatitis B therapy

https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration today approved Hibsago (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. Hibsago is approved for certain adults without cirrhosis who have been taking HBV antiviral therapy for at least six months, have suppressed levels of HBV in their blood and have hepatitis B surface antigen (HBsAg) levels of 3,000 IU/mL or less, as determined by an FDA-authorized test. “For many people living with chronic hepatitis B, treatment can mean taking antiviral medication for years to keep the virus suppressed,” said Wendy Carter, DO, Acting Director of the Office of Infectious Diseases in the Center for Drug Evaluation and Research. “Hibsago provides a new treatment approach that gives some patients the possibility of maintaining control of the virus after all chronic HBV treatment has ended. This approval represents an important advance for people living with this serious disease.” Chronic hepatitis B is a long-term liver infection caused by HBV. Over time, the infection can lead to serious liver disease, including cirrhosis, and increase the risk of liver cancer. Hibsago works by targeting the genetic instructions the virus uses to make copies of itself and viral proteins, helping reduce the amount of virus and hepatitis B surface antigen in the body. The FDA also authorized the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic device to aid in the selection of patients with chronic HBV infection for treatment with antiviral therapy in accordance with the FDA approved drug labeling and to assist in monitoring patients throughout the course of treatment. Researchers studied Hibsago in two clinical trials that compared it with a placebo, an inactive treatment. Hibsago is injected under the skin for up to 24 weeks. Patients take it alongside their existing hepatitis B medicine and continue that medicine for at least 24 weeks after their last Hibsago injection. Some patients may then be able to stop their existing medicine if they meet certain health and lab test requirements. Across the two trials, 24% of patients who received Hibsago met the requirements to stop their existing medicine, compared with none who received placebo. Twenty-four weeks after stopping all hepatitis B treatment, 19% of patients who received Hibsago still had the virus under control, and a protein that signals hepatitis B infection (HBsAg) could not be detected in their blood. Hibsago has a boxed warning for serious liver reactions as well as low platelet counts, which can increase the risk of potentially life-threatening bleeding. Hibsago also has warnings for worsening kidney function, serious inflammatory adverse reactions like vasculitis, and serious risks if the injection is not administered properly. Patients need regular blood tests and follow up with their healthcare provider before and during treatment to monitor these risks. The most common side effects, excluding laboratory abnormalities, are injection site reactions, fever, fatigue and headache. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track?utm_medium=email&utm_source=govdelivery

Optimizing Clinical Practice in Prostate Cancer (video series) +... +

Optimizing Clinical Practice in Prostate Cancer Advanced prostate cancer (PC) includes metastatic hormone-sensitive PC (mHSPC), nonmetastatic castration-resistant PC (nmCRPC), and metastatic castration-resistant PC (mCRPC). Management of these disease types differs, but the overall goal when treating them is the same: to prolong life, to delay disease progression, and to maintain quality of life for patients by minimizing symptoms. This Learning Center will focus on understanding the latest data in advanced PC, including innovations in androgen receptor-targeted (ART) therapy, radiopharmaceuticals, how to interpret the data for clinical practice, and what impact this may have on clinical decision-making and aligning treatment for the individual patient. https://www.medscape.org/advances/optimizing-clinical-practice-prostate-cancer-2026a1000jj9?src=mkmcmr_driv_32025_mscpedu_461680.01_ace_final&uac=148436CN The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations Authors: Neal D. Shore, MD, FACS; Sarah Caulfield, PharmD, BCOP; Rana R. McKay, MD, FASC https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?page=1&src=mkmcmr_driv_32025_mscpedu_461680.01_ace_final&uac=148436CN

Medscape Now! Cancer and Bone Health Screening: Evidence-Based Strategies for Older Adults Authors: Blessing Ajayi, PA-C (++)

Medscape Now! Cancer and Bone Health Screening: Evidence-Based Strategies for Older Adults Authors: Blessing Ajayi, PA-C https://www.medscape.org/viewarticle/medscape-now-cancer-and-bone-health-screening-evidence-based-2026a10012vq?page=1&src=wnl_tpal_261020_mscpedu&uac=148436CN&impID=8815023 Understanding Cancer and Bone Health Challenges in Aging Populations Population aging is a defining global trend, driven by longer lives, improved survival, and lower fertility.[1] The global population aged 65 years and older is projected to increase substantially, reaching about 17% of the world's population by 2050.[1] Cancer disproportionately affects older adults: More than 60% of patients with cancer are aged 65 years or older.[2] Knowledge gaps remain regarding the safest and most effective treatments for this population.[2] Aging increases bone loss in both women and men.[3] Estrogen deficiency is a major cause of accelerated bone loss; in breast cancer, estrogen deprivation decreases bone mineral density and raises fracture incidence by 40% to 50%.[3] Androgen-deprivation therapy (ADT) suppresses estrogen production and likewise accelerates bone loss and increases fracture rates.[3] Cytotoxic chemotherapy may also adversely affect bone metabolism.[3] Medscape NOW! Prehabilitation Before Major Abdominal Surgery: Exercise, Nutrition, and Outcomes Authors: ​Naseem Bazargan, MPH https://www.medscape.org/viewarticle/medscape-now-prehabilitation-before-major-abdominal-surgery-2026a10012w8?page=1&src=wnl_tpal_261020_mscpedu&uac=148436CN&impID=8815023 This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Med Op-Ed: Time Toxicity, Clinical Trial Access, and RECIST Edited by Victoria Stern

https://www.medscape.com/viewarticle/med-op-ed-time-toxicity-clinical-trial-access-and-recist-2026a10013hh In this installment of Med Op-Ed: The concept of time toxicity is morphing from patient- to stakeholder-centric, clinical trial access remains a challenge, and why it’s time to revisit Response Evaluation Criteria in Solid Tumors (RECIST).

Cutaneous T-Cell Lymphoma: Reduced US Incidence Rates Surprise Researchers John Jesitus (++) +...

Cutaneous T-Cell Lymphoma: Reduced US Incidence Rates Surprise Researchers John Jesitus https://www.medscape.com/viewarticle/cutaneous-t-cell-lymphoma-reduced-us-incidence-rates-2026a10013fc?src= A recent analysis showed that although age-adjusted US rates of cutaneous T-cell lymphoma (CTCL) incidence rose between 2000 and 2015, the number of cases declined from 2015 to 2022 — a timeframe marked by widespread use of biologic drugs that have raised concerns about potentially inducing or exacerbating CTCL. As an epidemiologic study, the analysis did not assess causality. However, authors and a CTCL expert agreed that it is plausible that dupilumab in particular might have accounted for at least some of the downturn. Watchful Waiting Has Lasting QOL Benefit in Rectal Cancer https://www.medscape.com/viewarticle/watchful-waiting-has-lasting-qol-benefit-rectal-cancer-2026a10013eh?src= Patients who are able to undergo watchful waiting instead of immediate surgery for locally advanced rectal cancer can see lasting gains in quality of life (QOL), according to a new analysis of two clinical trials. https://www.medscape.com/index/list_13474_0

Blood-Based CRC Test Upgrades Improve on Precancerous Lesion Detection Nancy A. Melville

https://www.medscape.com/viewarticle/blood-based-crc-test-upgrades-improve-precancerous-lesion-2026a10013i5?src= NASHVILLE, Tenn. — Updates to an FDA-approved colorectal cancer (CRC) blood test increased the detection of advanced precancerous lesions (APLs), a new study showed. “The updated test has improved performance, better detection of advanced precancerous lesions, resulting in larger projected reductions in CRC incidence and mortality at the population level,” said first author Aasma Shaukat, MD, MPH, of the NYU Grossman School of Medicine in New York City.

EMA Declines Pediatric Extension for AML Drug Edited by Joyani Das (+++)

https://www.medscape.com/viewarticle/ema-declines-pediatric-extension-aml-drug-2026a10013lb?src= Children with newly diagnosed acute myeloid leukemia (AML) in Europe will not gain a new targeted option for now. The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has finalized its assessment of an application to extend the use of Mylotarg (gemtuzumab ozogamicin, Pfizer) to children aged 1 year to less than 18 years with newly diagnosed AML, in combination with cytarabine and mitoxantrone. The committee did not recommend the new use. EMA Upholds Rejection of Posttransplant Complication Drug Edited by Joyani Das https://www.medscape.com/viewarticle/ema-upholds-rejection-posttransplant-complication-drug-2026a10013l6?src= The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has confirmed its recommendation to refuse marketing authorization for narsoplimab (Yartemlea, Omeros Ireland Limited) for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA). The opinion, adopted on October 15, 2026, follows a re-examination requested by the company after the committee’s initial negative opinion on June 25, 2026. EMA Backs Oral Suspension for Malignant Brain Tumors https://www.medscape.com/viewarticle/ema-backs-oral-suspension-malignant-brain-tumors-2026a10013l2?src= At its October 2026 meeting, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended Kizfizo (temozolomide, Orphelia Pharma) 40 mg/mL oral suspension for adults with newly diagnosed glioblastoma and for adults and children aged 1 year or older with recurrent or progressive malignant glioma. Kizfizo is a hybrid medicine of Temodal, the capsule formulation authorized in the EU since January 26, 1999. It contains the same active substance. The new product differs in being a 40 mg/mL suspension, and it extends approval to patients aged 1 year to less than 3 years.

Oncology Cases & Quizzes

Woman With Breast Angiosarcoma Responds to Paclitaxel An individualized paclitaxel strategy produced a complete response in one frail older woman with radiation-associated breast angiosarcoma. Medscape Global, October 19, 2026 https://www.medscape.com/index/list_12039_0

FDA Approves Dostarlimab for Rectal Cancer

https://www.medscape.com/viewarticle/fda-approves-dostarlimab-rectal-cancer-2026a10013c7?ecd=WNL_trdalrt_pos1_ous_261021_etid8816935&uac=148436CN&impID=8816935 The FDA has granted accelerated approval to dostarlimab (Jemperli, GSK) for rectal cancer indications. The drug is now approved for adults with stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR). The PD-1 inhibitor is the first immunotherapy to be approved specifically for MSI-H or dMMR rectal cancer, which accounts for 5%-10% of tumors. Based on the results of the approval study, AZUR-1, GSK said dostarlimab could help eligible patients avoid chemotherapy, radiation, and surgery.

American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting

https://www.medscape.com/c25/p14/american-society-radiation-oncology-astro-2026-annual-2026a1000rs5?ecd=wnl_conf_onc_ASTRO_NON-SPON_261021_mscpedit_etid8810519&uac=148436CN&impID=8810519

I was told it was anxiety–but it was Wilson’s disease

https://rarerevolutionmagazine.com/i-was-told-it-was-anxiety-but-it-was-wilsons-disease/ Aneesha Premkumar’s journey to diagnosis spanned several years. Her symptoms were attributed to anxiety and stress, but it turned out to be Wilson’s disease. She describes her life before and after diagnosis and highlights the importance of advocating for yourself Written by Aneesha Premkumar When I was diagnosed with Wilson’s disease on 2 February 2024, my life finally started to make sense. For a long time, I knew something wasn’t right, but I couldn’t understand why my body seemed to be changing in ways I couldn’t control. What started as small symptoms gradually became impossible to ignore. My speech began to change. I found myself mumbling words and struggling to communicate clearly. My handwriting became smaller and harder to read after only a few sentences. I developed tremors, experienced brain fog, and found it difficult to remember things. Walking became harder, and there were days when I needed support just to get around.

The Lancet Commission on 21st century global threats to health Prof Christopher J L Murray, DPhila,b,* Send email to cjlm@uw.edu ∙ Natalia Kanem, MDc,* ∙ Shameran Abed, Bar-at-Lawd ∙ Prof Ibrahim Abubakar, PhDe ∙ Ifedayo M Adetifa, PhDf,g,h ∙ Ximena P Aguilera, MDi ∙ et al.

The Lancet Commission on 21st century global threats to health Prof Christopher J L Murray, DPhila,b,* Send email to cjlm@uw.edu ∙ Natalia Kanem, MDc,* ∙ Shameran Abed, Bar-at-Lawd ∙ Prof Ibrahim Abubakar, PhDe ∙ Ifedayo M Adetifa, PhDf,g,h ∙ Ximena P Aguilera, MDi ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01714-9/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_whs26&_hsenc=p2ANqtz-8E2GSnz-zYNMa5ENjEvwqERZNe7ggCA8Mp-tDGeubMB0pJGBadraZGwnxkcCeU5ffZrBDOf_iExFcHqQI4jcQ9J-5n2w&_hsmi=443908007&utm_source=hs_email Editorial p1525 Rethinking threats to human survival The Lancet https://www.thelancet.com/journals/lancet/issue/vol408no10564/PIIS0140-6736(26)X2039-6

Cancer-related depression among Southwest American Indian survivors: a qualitative study Rey Paolo Ernesto J. Roca III1 , Wendie Robbins1 , Felicia Schanche Hodge1,2, (+ +...)

Cancer-related depression among Southwest American Indian survivors: a qualitative study Rey Paolo Ernesto J. Roca III1, Wendie Robbins1, Felicia Schanche Hodge1,2, https://www.academia.edu/3071-0324/2/3/10.20935/AcadPHealth8402?email_action=download Introduction: Depression is common among cancer survivors and may disrupt sleep, appetite, and daily functioning. American Indian and Alaska Native populations experience disproportionate cancer incidence and mortality for several cancers, including cervical, liver, and stomach cancer. These disparities are shaped by well-documented structural barriers, including limited access to quality care and a shortage of culturally responsive mental health services in American Indian and Alaska Native (AI/AN) communities. Limited research has examined how Indigenous cancer survivors understand and respond to depression within the context of cancer survivorship. https://www.academia.edu/3071-0324/2/3/10.20935/AcadPHealth8402 Long sleep duration and mortality among U.S. cancer survivors: NHIS-NDI linkage Tolulope Adebile, Purbasha Biswas, Temitayo Paul, Olamide Asifat, Xinyan Zhang, Jian Zhang, Lili Yu Volume 2, Issue 3 https://www.academia.edu/journals/academia-global-and-public-health/articles?source=journal-top-nav

Making dementia clinical trials more representative The Lancet Healthy Longevity (+...)

Making dementia clinical trials more representative The Lancet Healthy Longevity https://www.thelancet.com/journals/lanhl/issue/vol7no9/PIIS2666-7568(26)X2009-8

CAR T cells in autoimmunity: safety first The Lancet Rheumatology (+...)

CAR T cells in autoimmunity: safety first The Lancet Rheumatology https://www.thelancet.com/journals/lanrhe/issue/vol8no11/PIIS2665-9913(26)X2010-0

Viewpoint: Why taxes, regulations, and scare tactics won’t convert people into eating healthier Economist | October 20, 2026

https://geneticliteracyproject.org/2026/10/20/viewpoint-why-taxes-regulations-and-scare-tactics-wont-convert-people-into-eating-healthier/ Decades of gentle nudging haven’t slowed the global obesity epidemic, so governments are getting pushier — slapping warning labels on junk food, taxing it, and restricting where it can be sold, as The Economist reports.

Vaccines, religious freedom, and protecting children’s health: New York Amish appeal to Supreme Court after $118,000 in vaccine fines for blocking shots Reason | October 20, 2026

https://geneticliteracyproject.org/2026/10/20/vaccines-religious-freedom-and-protecting-childrens-health-new-york-amish-appeal-to-supreme-court-after-118000-in-vaccine-fines-for-blocking-shots/ New York’s Amish are taking their fight over school vaccine mandates to the US Supreme Court, after the state hit three rural Amish schoolhouses with $118,000 in fines for enrolling unvaccinated students, as Reason’s Ryan Curtis reports.

Challenging creation of a ‘vaccine injury clinic,’ NIH research scientists rebuke Kennedy for politicizing and undermining science New York Times | October 20, 2026

https://geneticliteracyproject.org/2026/10/20/challenging-creation-of-a-vaccine-injury-clinic-nih-research-scientists-rebuke-kennedy-for-politicizing-and-undermining-science/ The board that oversees the National Institutes of Health’s research hospital has publicly rebuked Health Secretary Robert F. Kennedy Jr., voting unanimously to back a statement from its chairman accusing Kennedy of undermining trust in science and politicizing the hospital’s work, as The New York Times’ Sheryl Gay Stolberg reports.

Testosterone’s growing appeal to women: It anecdotally mildly improves sex life, but are there any other potential benefits—or red flags? Daniel Kelly | October 20, 2026

https://geneticliteracyproject.org/2026/10/20/testosterones-growing-appeal-to-women-it-anecdotally-mildly-improves-sex-life-but-are-there-any-other-potential-benefits-or-red-flags/ A recent BBC report described women posing as men to get hold of testosterone gel, hoping to improve their menopause symptoms, because female testosterone products are not easily available to them. But why is the appetite for this predominantly male hormone exploding and are there risks involved?

RFK Jr.’s EPA capitulates to anti-abortionists, authorizes study of safe abortion pills which activists falsely claim are “poisoning” our water supply Jenae Barnes | October 20, 2026

https://geneticliteracyproject.org/2026/10/20/rfk-jr-s-epa-capitulates-to-anti-abortion-activists-authorizes-study-of-safe-abortion-pills-mifepristone-and-misoprostol-which-they-claim-are-poisoning-americas-w/ After pressure from anti-abortion advocates, Republican lawmakers and state officials, the Environmental Protection Agency announced this month that it will launch a study to test for trace amounts of abortion pills as a water contaminant in multiple cities. Scientists say there’s no evidence that mifepristone and misoprostol, the two-drug regimen that is highly effective in ending a pregnancy, harms the environment or people.

FDA Approves Gazyva (Obinutuzumab) for Treatment of Childhood-Onset Idiopathic Nephrotic Syndrome by Madaline Spencer| Published on: Oct 1, 2026

https://checkrare.com/fda-approves-gazyva-obinutuzumab-for-treatment-of-childhood-onset-idiopathic-nephrotic-syndrome/ The US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. INS is a rare, autoimmune kidney disease characterized by unpredictable relapses that cause fatigue, swelling, weight gain and increased susceptibility to infections and clotting, as well as anxiety, depression and reduced self-esteem, brought on by the fear of relapse and social isolation. It is usually diagnosed in early childhood and is the most common form of primary glomerular disease in children. FDA Approves Gazyva for Idiopathic Nephrotic Syndrome, Offering a New Treatment Option by Madaline Spencer| Published on: Oct 14, 2026 Keisha L. Gibson, MD, MPH, pediatric nephrologist at the UNC School of Medicine, discusses the approval of Gazyva (obinutuzumab) for patients with childhood-onset idiopathic nephrotic syndrome (INS). https://checkrare.com/fda-approves-gazyva-for-idiopathic-nephrotic-syndrome-offering-a-new-treatment-option/

FDA Approves Jaypirca (Pirtobrutinib) for Two Rare Blood Cancers by Madaline Spencer| Published on: Oct 13, 2026

https://checkrare.com/fda-approves-jaypirca-pirtobrutinib-for-two-rare-blood-cancers/ The US Food and Drug Administration (FDA) has approved pirtobrutinib for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. CLL/SLL are rare cancers that affect B lymphocytes. The conditions are similar in pathophysiology but differ primarily in location of the disease. In patients with CLL, the cancer mainly manifests in the bloodstream, while in patients with SLL, it is in the lymph nodes and lymphoid tissue. CLL accounts for the majority (90%) of cases. Early signs and symptoms may include swollen lymph nodes, fatigue, weight loss, fever, night sweats and/or frequent...

Myasthenia Gravis Clinical Research Highlights

https://checkrare.com/learning/p-myasthenia-gravis-clinical-research-highlights-2026/

Beyond AChR: Recognizing and Treating MuSK Ab+, LRP4 Ab+ and Triple Seronegative Myasthenia Gravis

https://checkrare.com/learning/p-beyond-achr-recognizing-and-treating-musk-ab-lrp4-ab-and-triple-seronegative-myasthenia-gravis/

KAT6 Syndromes by CheckRare Staff| Published on: Sep 24, 2026 KAT6 syndromes are rare genetic neurodevelopmental disorders caused by genetic mutations in the KAT6A or KAT6B genes.

KAT6 Syndromes by CheckRare Staff| Published on: Sep 24, 2026 KAT6 syndromes are rare genetic neurodevelopmental disorders caused by genetic mutations in the KAT6A or KAT6B genes. https://checkrare.com/kat6-syndromes/

Breakthrough Therapy Designation to Cimzia for Antiphospholipid Syndrome

FDA Grants Breakthrough Therapy Designation to Cimzia for Pregnancy Complications in Antiphospholipid Syndrome by Madaline Spencer| Published on: Oct 16, 2026 https://checkrare.com/fda-grants-breakthrough-therapy-designation-to-cimzia-for-pregnancy-complications-in-antiphospholipid-syndrome/ Jane Salmon, MD, Professor of Medicine at Weill Cornell Medical College, discusses antiphospholipid syndrome (APS), its impact on pregnancy, and emerging research into Cimzia (certolizumab pegol) as a potential approach to preventing serious pregnancy complications.

Efficacy of Infigratinib on Achondroplasia by Madaline Spencer| Published on: Oct 19, 2026

Efficacy of Infigratinib on Achondroplasia by Madaline Spencer| Published on: Oct 19, 2026 Daniela Rogoff, MD, PhD, Chief Medical Officer, Skeletal Dysplasia of BridgeBio, discusses the efficacy of infigratinib to treat persons with achondroplasia. https://checkrare.com/efficacy-of-infigratinib-on-achondroplasia/

Efficacy of Vosoritide to Treat Hypochondroplasia by Madaline Spencer| Published on: Oct 20, 2026

Efficacy of Vosoritide to Treat Hypochondroplasia by Madaline Spencer| Published on: Oct 20, 2026 Andrew Dauber, MD, MMsc, Chief of Endocrinology at Children’s National, discusses the efficacy of vosoritide to treat persons with hypochondroplasia. https://checkrare.com/efficacy-of-vosoritide-to-treat-hypochondroplasia/

Ultragenyx Sells PRV for $210M | The CheckRare Brief Ep 11 by CheckRare Staff| Published on: Oct 14, 2026

Ultragenyx Sells PRV for $210M | The CheckRare Brief Ep 11 by CheckRare Staff| Published on: Oct 14, 2026 In this episode, we discuss Ultragenyx’s Priority Review Voucher that sold for $210 million, the efficacy of newborn screening on MLD, and ethical considerations needed to design and conduct clinical trials. https://checkrare.com/ultragenyx-sells-prv-for-210m-the-checkrare-brief-ep-11/

Classical homocystinuria (HCU) HCU—2027 and beyond!

https://rarerevolutionmagazine.com/digitalspotlight/hcu-2027-and-beyond/ Written by Karen Roberts and Nicola Miller, RARE Revolution Interview with Tara Morrison, director of HCU Network Australia, Danaé Bartke, executive director HCU Network America Sarah Jones, community lead, Metabolic Support Classical HCU causes a deficiency of cystathionine beta-synthase (CBS). Without enough CBS, the amino acids homocysteine and methionine build up in the blood. HCU can cause complications such as stroke, pulmonary embolism and deep vein thrombosis, ophthalmologic and skeletal complications, as well as developmental delay. Treatment may consist of vitamin supplementation, dietary restrictions, medication and an amino acid formula. Newborn screening for the condition is available, albeit inconsistent globally, and cases of missed diagnoses have been reported.

An RNA splicing factor could help reverse cellular aging A machine learning-based screen identified SRSF1 as a potential target for reversing several hallmarks of aging without erasing cell identity, with further testing revealing benefits in aged mice. Written byBree Foster, PhD

An RNA splicing factor could help reverse cellular aging A machine learning-based screen identified SRSF1 as a potential target for reversing several hallmarks of aging without erasing cell identity, with further testing revealing benefits in aged mice. Written byBree Foster, PhD https://www.drugdiscoverynews.com/an-rna-splicing-factor-could-help-reverse-cellular-aging-17593 Aging gradually erodes the function of cells, tissues, and organs, increasing the risk of chronic diseases such as cardiovascular disease, neurodegeneration, and cancer. Researchers are therefore investigating ways to reverse age-related changes without disrupting normal cellular function.

FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer?utm_medium=email&utm_source=govdelivery On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GlaxoSmithKline LLC) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA authorized test for solid tumors.

Digital Breast Tomosynthesis Screening Reduces Interval Cancers by 24% but Not Significantly

https://www.medscape.com/viewarticle/digital-breast-tomosynthesis-screening-reduces-interval-2026a10012r5?src= Digital breast tomosynthesis (DBT) plus synthesised mammography lowered the 24-month invasive interval cancer rate by 24% compared with digital mammography among women aged 50-70 years in a randomised screening trial, but the difference was not statistically significant.

Intratumoral Immunotherapy Draws Renewed Attention but Does It Work? Kate Johnson

https://www.medscape.com/viewarticle/intratumoral-immunotherapy-draws-renewed-attention-does-it-2026a10012vx After years on the margins, intratumoral immunotherapy is drawing renewed attention following the FDA’s recent approval of vusolimogene oderparepvec (Tudriqev, Replimune), the second immunotherapy approved for intratumoral use. The drug is approved in combination with nivolumab to treat advanced melanoma that has progressed after an anti-PD-1-containing regimen.

Yoghurt, coffee and chocolate have something in common, and researchers mapped it across Europe

https://www.news-medical.net/news/20261018/Yoghurt-coffee-and-chocolate-have-something-in-common-and-researchers-mapped-it-across-Europe.aspx From yoghurt and sourdough to coffee and chocolate, a survey spanning 53 European countries examines which fermented foods people consume and how much they actually eat.

Could ultraprocessed foods affect your brain before you notice?

https://www.news-medical.net/news/20261019/Could-ultraprocessed-foods-affect-your-brain-before-you-notice.aspx Could what's on your plate affect your brain before your memory shows any signs of trouble? A study of nearly 9,000 Canadian adults links higher ultraprocessed food intake to greater body fat and signs of silent vascular brain injury, although the brain findings warrant caution.

Menopause isn't the end of the story for the ovaries

https://www.news-medical.net/news/20261019/Menopause-isnt-the-end-of-the-story-for-the-ovaries.aspx Long after their reproductive role ends, ovaries continue to undergo molecular changes linked to inflammation, tissue remodeling, and cellular signaling, raising new questions about their potential influence on women's health as they age.

How GLP-1 Drugs May Help Treat Addiction: Mechanisms and Clinical Evidence

https://www.news-medical.net/health/How-GLP-1-Drugs-May-Help-Treat-Addiction-Mechanisms-and-Clinical-Evidence.aspx Shared pathways linking metabolism, reward, and substance seeking are prompting scientists to investigate diabetes and obesity drugs as potential addiction treatments. Substance use disorders (SUDs) represent a substantial global health burden, with an estimated 400 million people living with alcohol use disorder (AUD) worldwide reported in 2019.2 The high relapse rates of SUDs and limited pharmacological options for some substances support the need for additional treatments, alongside wider access to established care.

GLP-1 Drugs and Obstructive Sleep Apnea: How Weight Loss Medications Improve Breathing During Sleep

https://www.news-medical.net/health/GLP-1-Drugs-and-Obstructive-Sleep-Apnea-How-Weight-Loss-Medications-Improve-Breathing-During-Sleep.aspx What can treatments targeting weight and metabolism offer people with obstructive sleep apnea, and which questions must clinical trials still answer? Obstructive sleep apnea (OSA) is characterized by recurrent collapse of the upper airway during sleep, causing repeated airflow obstruction and leading to loud snoring, frequent awakenings, and excessive daytime sleepiness. Over time, fragmented sleep and recurrent nocturnal awakenings contribute to chronic fatigue, reduced energy levels, and impaired quality of life.

Gut Microbiome and Aging: How Gut Bacteria Influence Health and Longevity

Gut Microbiome and Aging: How Gut Bacteria Influence Health and Longevity https://www.news-medical.net/health/Gut-Microbiome-and-Aging-How-Gut-Bacteria-Influence-Health-and-Longevity.aspx From microbial shifts in later life to the distinctive gut communities of centenarians, researchers are investigating what the intestinal microbes reveal about how people age. The gut microbiota comprises a diverse community of microorganisms that regulate metabolism, support immune function, preserve intestinal barrier integrity, and influence inflammatory responses throughout life. Disruptions in gut microbiome composition can alter microbial homeostasis, the balance of microbial activity within the gut, increase inflammation, and affect the risk of age-related diseases.2

Could this flowering plant help people lose body fat?

https://www.news-medical.net/news/20261019/Could-this-flowering-plant-help-people-lose-body-fat.aspx A 12-week clinical trial found that adults taking Lythrum salicaria extract lost body fat while placebo recipients gained it, offering early evidence of a potential plant-based approach to weight management. A recent Nutrients study evaluated the efficacy and safety of Lythrum salicaria extract supplementation in reducing body fat in adults with a body mass index (BMI) of 23–30 kg/m².

GLP-1s and Skin Cancer: What Dermatologists Should Know (+...)

https://www.medscape.com/c32/p14/cutis-october-2026-2026a10010ly?ecd=mkm_ret_261017_mscpmrk_derm_cutis-top-content_etid8804153&uac=148436CN&impID=8804153 The Role of Antidiabetic Drugs in Cutaneous Malignancies: An Evidence-Based Review Seanna Yang, MD; Nickoulet Babaei, MD; Dahyeon Kim, MD; Mireya Cervantes, MD; Minka Gill, MD; Jashin J. Wu, MD https://www.medscape.com/viewarticle/role-antidiabetic-drugs-cutaneous-malignancies-evidence-2026a100106u?ecd=mkm_ret_261017_mscpmrk_derm_cutis-top-content_etid8804153&uac=148436CN&impID=8804153

Caribou halts its allogeneic CAR T programs as funding dries up Facing a tight financing market, the CRISPR biotech will wind down two off-the-shelf cell therapies as investor money shifts toward in vivo CAR T. Written byAndrea Corona

Caribou halts its allogeneic CAR T programs as funding dries up Facing a tight financing market, the CRISPR biotech will wind down two off-the-shelf cell therapies as investor money shifts toward in vivo CAR T. Written byAndrea Corona https://www.drugdiscoverynews.com/caribou-halts-its-allogeneic-car-t-programs-as-funding-dries-up-17584?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_VKkkojNK1QpvONG19i16LDx1hyhVxpBuGF9WqsjO_WAAxM-6O8sg2-UCZz0I2nOOLWiRPOzAFFRmK9cTfxw-i_CrfSg&_hsmi=444630187&utm_content=444630187&utm_source=hs_email For years, allogeneic CAR T cell therapy carried one of the field’s biggest promises: cancer-fighting cells made from healthy donors, stocked in advance, and ready the moment a patient needed them. Caribou Biosciences built its pipeline around that vision, using CRISPR genome editing to engineer donor cells that could persist and fight tumors. On October 6th, the company announced it would shelve both of its allogeneic chimeric antigen receptor (CAR) T cell therapy programs, including one ready for a Phase 3 trial.

Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD

Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?page=1&src=mkmcmr_driv_stan_mscpedu_261018-OUS-HONC-enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46-cta&uac=148436CN

Menopause (+++)...

https://womenshealth.gov/menopause?utm_medium=email&utm_source=govdelivery Menopause is a normal stage of life. Symptoms are real, and treatments can help. Find current information here to help you when talking with your health care provider. Today is the first day of National Women’s Blood Pressure Awareness Week (NWBPAW)! From October 18 to 24, the U.S. Department of Health and Human Services, Office on Women’s Health highlights priorities for supporting women’s heart health and encourages women to take charge of their blood pressure.    The 2026 theme, “Strong Hearts: Everyday Actions for Blood Pressure Control and Lifelong Health,” emphasizes making heart‑healthy habits part of everyday life. The theme highlights practical actions women can take to manage healthy blood pressure and protect their heart health while reinforcing the connection between blood pressure and chronic disease risk across the lifespan. It also highlights key life transitions, including pregnancy, the postpartum period, and perimenopause/menopause, when blood pressure can change. https://www.cdc.gov/pregnancy/after/index.html?utm_medium=email&utm_source=govdelivery This year’s focus areas include:  Nutrition & Blood Pressure: Putting Healthy Eating into Practice Lifestyle & Digital Wellness: Everyday Behaviors that Influence Heart Health Prevention & Women’s Heart Health: Reducing Risk Across the Life Course Reversing Chronic Conditions: Improving Health Through Prevention & Action  National Women’s Blood Pressure Awareness Week 2026 https://womenshealth.gov/nwbpaw?utm_medium=email&utm_source=govdelivery

Translating Molecular Insights Into Practice for HR-Positive/HER2-Negative Metastatic Breast Cancer Authors: Hope Rugo, MD; Peter A. Fasching, MD

https://www.medscape.org/viewarticle/translating-molecular-insights-practice-hr-positive-her2-2026a1000y0g?page=1&src=mkmcmr_driv_32025_mscpedu_451770.18_ace_launch&uac=148436CN

CURATIVE POTENTIAL NOW IN 2L DLBCL

https://global.columvi-hcp.com/?cid=na1191708001&utm_source=medscape&utm_medium=na&utm_campaign=columvi2026&utm_content=tx%3Aagenative%3A2603%3Axx&dclid=CjkKEQjw_9bWBhDiscOaku6CnKkBEiQAKCg80nE2km_tXx8jxv0bSnvbxCJY14soZkwxNvGTx15fUMTw_wcB&gad_source=7&gad_campaignid=23680757487 At 3 years, regardless of your patient’s age or relapse time in 2L DLBCL, COLUMVI + GemOx demonstrates sustained survival benefit. And it’s well tolerated. Be confident with the first and only approved off-the-shelf therapy with curative potential in 2L DLBCL https://www.medscape.com/invitation/viewTracker.do?src=inve&uac=148436CN

PHESGO: Proven efficacy and a convenient method of administration Subcutaneous administration in minutes, without compromising on efficacy

HER2-targeted therapies have transformed the HER2+ breast cancer landscape Give your patients a proven treatment approach that balances efficacy with well-established safety profiles, keeping your patients' quality of life at the centre of your treatment approach. https://global.phesgo-hcp.com/?cid=na7759503509&utm_source=medscape&utm_medium=na&utm_campaign=her2_2026&utm_content=tx%3Aphesgonc5%3A2609%3Axx&dclid=CjkKEQjw_9bWBhDiscOaku6CnKkBEiQAKCg80ktc7Kj_Slf6KPtBQnPnT8UVfo34wD9aElkpGuCBeofw_wcB&gad_source=7

Reshaping Gastroesophageal Adenocarcinoma Care: Integrating New Anti-HER2 Therapies CME/CNE/CPE/IPCE Monday, November 9, 2026 | 3:30 pm - 4:15 pm ET Virtual

https://na.eventscloud.com/website/99132/ Transform your gastroesophageal adenocarcinoma (GEA) practice by joining expert oncologists Elena Elimova, Samuel J. Klempner, and Kohei Shitara for an interactive, 45-minute online discussion. Unpack the latest clinical trial data for novel anti-human epidermal growth factor receptor 2 (HER2) regimens, learn how to integrate new frontline regimens into care for patients with HER2-positive GEA, and gain insight into postprogression strategies. Faculty will also discuss proactive team-based approaches to toxicity management. Register now to elevate your clinical decision-making.

The Fifth Transatlantic Exchange in Oncology: Transatlantic Innovations in Cancer Drug Research – A Selection of Key Presentations From the Event (video series)

https://www.medscape.com/medicalaffairs/448002.4/media-5?src=0_nl_sm_0&uac=148436CN The Fifth Annual Transatlantic Exchange in Oncology reflects an ongoing collaboration between key scientists, clinicians, and researchers from the Institut Gustave Roussy in Villejuif, France and Dana-Farber Cancer Institute (DFCI) in Boston, USA (supported by L’Institut Servier). This year’s event brought together a global audience with expertise in medical oncology, translational research, and molecular biology to exchange and discuss insights and new developments in the rapidly evolving area of cancer drug research. The event was held in Boston – at the Jimmy Fund Auditorium at DFCI - on March 27, 2026. Prof Eric Fischer from DFCI gave his insights on the day with this short “Expert Commentary” on the program. Prof Toni Choueiri then provides the Welcome Address. This is followed by 4 videos from the day’s events which reflect the depth and diversity of cancer drug research and collaboration across the Atlantic.

The Rock's protein-heavy post-workout smoothie may not be right for everyone

The Rock's protein-heavy post-workout smoothie may not be right for everyone https://www.foxnews.com/lifestyle The Rock's protein-heavy post-workout smoothie may not be right for everyone Dietitian says star's protein-packed drink offers nutritional benefits, but some ingredients may be excessive for others By Sadie Chafe Fox News Published October 19, 2026 6:00am EDT | Updated October 19, 2026 6:30am EDT https://www.foxnews.com/food-drink/rocks-protein-heavy-post-workout-smoothie-may-not-right-everyone

Popular foods Americans eat every day linked to silent brain damage, alarming study finds

Popular foods Americans eat every day linked to silent brain damage, alarming study finds https://www.foxnews.com/health Researchers say the link between ultra-processed foods and brain health problems may be detectable before symptoms appear By Sadie Chafe Fox News Published October 18, 2026 1:07pm EDT | Updated October 18, 2026 1:39pm EDT https://www.foxnews.com/health/popular-foods-americans-eat-every-day-linked-silent-brain-damage-alarming-study-finds